MedTrace Logo

Genomic and Epigenomic Alterations After Cancer Treatment in Pregnancy

NCT04125446 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2022-09-27

No results posted yet for this study

Summary

The investigators want to obtain a fundamental understanding if and which chemotherapeutic agents used for treating cancer during pregnancy are associated with placental and/or offspring (epi)genetic changes, potentially causing FGR and childhood/adult diseases later in life.

Conditions

Sponsors & Collaborators

  • University Hospital, Antwerp

    collaborator OTHER

  • University Hospital, Ghent

    collaborator OTHER

  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    collaborator OTHER

  • University Hospital, Gasthuisberg

    lead OTHER

Principal Investigators

  • Frédéric Amant, MD,PhD · Universitaire Ziekenhuizen KU Leuven

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-15
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04125446 on ClinicalTrials.gov